From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development

Chai Discovery has emerged as a prominent AI drug research company, securing a major partnership with pharmaceutical giant Eli Lilly. The startup, which originated from OpenAI's offices, has gained backing from top Silicon Valley venture capital firms. This collaboration highlights growing pharmaceutical industry investment in AI-driven drug discovery, positioning Chai Discovery at the forefront of AI-enabled medicinal research and development.